VAV2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Alternative names
Guanine nucleotide exchange factor VAV2, Oncogene VAV2, Protein vav 2, VAV2_HUMAN, Vav 2 oncogene
What's included?
Recommended products
VAV2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- VAV2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VAV2 also known as Vav 2 guanine nucleotide exchange factor is a member of the VAV family of proteins which function as guanine nucleotide exchange factors (GEFs). It has a molecular mass of approximately 100 kDa. The protein converts inactive GDP-bound Rho family GTPases such as Rac1 and Cdc42 into their active GTP-bound form. VAV2 is expressed in various tissues including the brain heart and lung indicating its broad role in cellular signaling across different systems.
- Biological function summary
VAV2 influences multiple cellular processes through its role as a GEF. This protein does not form a part of a static complex but interacts dynamically with other signaling components. VAV2 regulates cytoskeleton organization cell migration and growth by activating Rho family GTPases. Its activity impacts processes such as neuronal development and immune response by modifying the actin cytoskeleton which is important for cell movement and morphological changes.
- Pathways
VAV2 plays an integral role in signaling cascades like the Ras and MAPK pathways. It interacts closely with proteins like Rac1 and Cdc42 to propagate signals that influence cell proliferation and survival. By facilitating the switch from inactive GDP-bound states to active GTP-bound forms of Rho GTPases VAV2 integrates signals from cell surface receptors to downstream effectors that mediate cellular responses to external stimuli.
- Associated diseases and disorders
VAV2’s function connects to cancer progression and cardiovascular disorders. Changes in VAV2 expression or activity can lead to abnormal cell growth and differentiation linking it to cancerous transformations. Additionally because VAV2 modulates cell migration and cytoskeletal dynamics its malfunction can contribute to cardiovascular diseases by affecting vascular smooth muscle cells and endothelial cells. In both contexts VAV2's interactions with Rho family proteins like Rac1 highlights its influence in disease mechanisms.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human VAV2 knockout HeLa cell lysate (ab257794)
Lane 1: Wild-type HeLa cell lysate (20µg)
Lane 2: VAV2 knockout HeLa cell lysate (20µg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-VAV2 antibody [EP1067Y] ab52640 observed at 100 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-VAV2 antibody [EP1067Y] ab52640 Anti-VAV2 antibody [EP1067Y] was shown to specifically react with VAV2 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human VAV2 knockout HeLa cell line ab265318 (knockout cell lysate ab257794) was used. Wild-type and VAV2 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-VAV2 antibody [EP1067Y] ab52640 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 20000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-VAV2 antibody [EP1067Y] (Anti-VAV2 antibody [EP1067Y] ab52640) at 1/20000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: VAV2 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 101 kDa
Observed band size: 100 kDa
Sanger Sequencing - Human VAV2 knockout HeLa cell lysate (ab257794)
Homozygous: 1 bp insertion in exon3
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com